In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models

Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells

(2010) AnLi Zhang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2

(2009) Yang Liu et al.   Acta Crystallographica Section F-Structural Biology and Crystallization Communications

Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression

(2009) Ingrid A. Mayer   Clinical Breast Cancer

Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab

(2009) E. Yao et al.   CLINICAL CANCER RESEARCH

HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin Phosphorylation

(2009) Jesús García-Castillo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

(2009) T. Ben-Kasus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ten years of HER2-directed therapy: still questions after all these years

(2008) Ian E. Krop et al.   BREAST CANCER RESEARCH AND TREATMENT

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model

(2008) Calin D. Dumitru et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY